Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INNOVATE: Biomarker Optimization of Neoadjuvant Therapy in HER2+ Breast Cancer
NCT06441890Phase 2Recruiting
- Sponsor
- University of Illinois Chicago
- Start
- Dec 2024
- Primary completion
- Jun 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of Paclitaxel Micelles for Injection, paclitaxel, docetaxel, trastuzumab, pertuzumab in HER2-positive breast cancer, sponsored by University of Illinois Chicago. Started Dec 2024; status: recruiting.
02
Drugs
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT06441890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06441890.